MA31204B1 - Sels d'addition acides, hydrates et polymorphes d'ethylamide d'acide 5-(2,4-dihydroxy-5-isopropyl-phenyl) -4-(4-morpholin-4-ylmethyl-phenyl)-isoxazole-3-carboxylique et preparations comprenant ces formes - Google Patents
Sels d'addition acides, hydrates et polymorphes d'ethylamide d'acide 5-(2,4-dihydroxy-5-isopropyl-phenyl) -4-(4-morpholin-4-ylmethyl-phenyl)-isoxazole-3-carboxylique et preparations comprenant ces formesInfo
- Publication number
- MA31204B1 MA31204B1 MA32191A MA32191A MA31204B1 MA 31204 B1 MA31204 B1 MA 31204B1 MA 32191 A MA32191 A MA 32191A MA 32191 A MA32191 A MA 32191A MA 31204 B1 MA31204 B1 MA 31204B1
- Authority
- MA
- Morocco
- Prior art keywords
- phenyl
- forms
- polymorphs
- morpholin
- isoxazole
- Prior art date
Links
- 150000003839 salts Chemical class 0.000 title abstract 7
- 238000002360 preparation method Methods 0.000 title abstract 3
- 150000004677 hydrates Chemical class 0.000 title abstract 2
- VJZBSHKIQOPPRU-UHFFFAOYSA-N 5-(2,4-dihydroxy-5-propan-2-ylphenyl)-4-[4-(morpholin-4-ylmethyl)phenyl]-1,2-oxazole-3-carboxylic acid Chemical compound C1=C(O)C(C(C)C)=CC(C2=C(C(C(O)=O)=NO2)C=2C=CC(CN3CCOCC3)=CC=2)=C1O VJZBSHKIQOPPRU-UHFFFAOYSA-N 0.000 title 1
- JLLYLQLDYORLBB-UHFFFAOYSA-N 5-bromo-n-methylthiophene-2-sulfonamide Chemical compound CNS(=O)(=O)C1=CC=C(Br)S1 JLLYLQLDYORLBB-UHFFFAOYSA-N 0.000 title 1
- 101100016370 Danio rerio hsp90a.1 gene Proteins 0.000 abstract 2
- 101100285708 Dictyostelium discoideum hspD gene Proteins 0.000 abstract 2
- 101100071627 Schizosaccharomyces pombe (strain 972 / ATCC 24843) swo1 gene Proteins 0.000 abstract 2
- NDAZATDQFDPQBD-UHFFFAOYSA-N luminespib Chemical class CCNC(=O)C1=NOC(C=2C(=CC(O)=C(C(C)C)C=2)O)=C1C(C=C1)=CC=C1CN1CCOCC1 NDAZATDQFDPQBD-UHFFFAOYSA-N 0.000 abstract 2
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 abstract 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 abstract 1
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 abstract 1
- 229910019142 PO4 Inorganic materials 0.000 abstract 1
- 239000007864 aqueous solution Substances 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 239000011521 glass Substances 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 abstract 1
- 239000010452 phosphate Substances 0.000 abstract 1
- 229940095064 tartrate Drugs 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
- C07D295/14—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D295/155—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with the ring nitrogen atoms and the carbon atoms with three bonds to hetero atoms separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
- C07D261/02—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
- C07D261/06—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members
- C07D261/10—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D261/18—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
La présente invention concerne de nouvelles formes de sels d'éthylamide d'acide 5-(2,4-dihydroxy-5-isopropyl-phényl)-4-(4-morpholin-4-ylméthyl-phényl)-isoxazole-3-carboxylique, en particulier leur sel mésylate, chlorhydrate, tartrate, phosphate et hémifumarate; des formes cristallines de ces sels; des polymorphes d'éthylamide d'acide 5-(2,4-dihydroxy-5-isopropyl-phényl)-4-(4-morpholin-4-ylméthyl-phényl)-isoxazole-3-carboxylique; des hydrates et des polymorphes de ces nouvelles formes de sels décrites ci-dessus; l'utilisation de ces nouvelles formes de sels décrites ci-dessus pour la mise au point d'un médicament destiné au traitement d'un trouble induit par la hsp90; une méthode de traitement d'un trouble induit par la hsp90 dans laquelle ces nouvelles formes de sels sont utilisées; des préparations comprenant ces formes de sels, en particulier des solutions aqueuses pouvant être administrées par voie intraveineuse; ainsi que des contenants en verre ambré remplis avec ces préparations.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP07103346 | 2007-03-01 | ||
| PCT/EP2008/052443 WO2008104595A1 (fr) | 2007-03-01 | 2008-02-28 | Sels d'addition acides, hydrates et polymorphes d'éthylamide d'acide 5-(2,4-dihydroxy-5-isopropyl-phényl)-4-(4-morpholin-4-ylméthyl-phényl)-isoxazole-3-carboxylique et préparations comprenant ces formes |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MA31204B1 true MA31204B1 (fr) | 2010-02-01 |
Family
ID=38134307
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA32191A MA31204B1 (fr) | 2007-03-01 | 2009-08-31 | Sels d'addition acides, hydrates et polymorphes d'ethylamide d'acide 5-(2,4-dihydroxy-5-isopropyl-phenyl) -4-(4-morpholin-4-ylmethyl-phenyl)-isoxazole-3-carboxylique et preparations comprenant ces formes |
Country Status (40)
| Country | Link |
|---|---|
| US (3) | US8163747B2 (fr) |
| EP (2) | EP2131845B1 (fr) |
| JP (1) | JP2010520176A (fr) |
| KR (1) | KR20090122218A (fr) |
| CN (2) | CN101636162A (fr) |
| AR (1) | AR065519A1 (fr) |
| AT (1) | ATE552836T1 (fr) |
| AU (1) | AU2008220800B2 (fr) |
| BR (1) | BRPI0807992A2 (fr) |
| CA (1) | CA2678043A1 (fr) |
| CL (1) | CL2008000618A1 (fr) |
| CO (1) | CO6210828A2 (fr) |
| CR (1) | CR10989A (fr) |
| CY (1) | CY1113805T1 (fr) |
| DK (1) | DK2131845T3 (fr) |
| DO (1) | DOP2009000209A (fr) |
| EA (1) | EA017075B1 (fr) |
| EC (1) | ECSP099602A (fr) |
| ES (1) | ES2384906T3 (fr) |
| GE (1) | GEP20115309B (fr) |
| GT (1) | GT200900236A (fr) |
| HR (1) | HRP20120535T1 (fr) |
| IL (1) | IL200401A0 (fr) |
| MA (1) | MA31204B1 (fr) |
| MX (1) | MX2009009233A (fr) |
| NI (1) | NI200900161A (fr) |
| NZ (1) | NZ578854A (fr) |
| PA (1) | PA8771101A1 (fr) |
| PE (1) | PE20090166A1 (fr) |
| PL (1) | PL2131845T3 (fr) |
| PT (1) | PT2131845E (fr) |
| RS (1) | RS52351B (fr) |
| SI (1) | SI2131845T1 (fr) |
| SM (1) | SMAP200900080A (fr) |
| TN (1) | TN2009000357A1 (fr) |
| TW (1) | TW200844102A (fr) |
| UA (1) | UA101950C2 (fr) |
| UY (1) | UY30943A1 (fr) |
| WO (1) | WO2008104595A1 (fr) |
| ZA (1) | ZA200905417B (fr) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW200922595A (en) * | 2007-10-12 | 2009-06-01 | Novartis Ag | Organic compounds |
| TWI450898B (zh) * | 2008-07-04 | 2014-09-01 | Sigma Tau Res Switzerland Sa | 具有抗腫瘤活性之芳基異唑化合物 |
| US8309578B2 (en) | 2008-11-25 | 2012-11-13 | Nerviano Medical Sciences S.R.L. | Bicyclic pyrazole and isoxazole derivatives as antitumor and antineurodegenerative agents |
| CA2786824C (fr) * | 2010-01-21 | 2018-04-10 | Aprea Ab | Solution aqueuse renfermant des 3-quinuclidinones en vue du traitement de maladie hyperproliferative, auto-immune et cardiaque |
| CN102753546A (zh) * | 2010-02-17 | 2012-10-24 | 日东制药株式会社 | 新型5-元杂环衍生物及其制备方法 |
| KR20120031854A (ko) | 2010-09-27 | 2012-04-04 | 한국전자통신연구원 | 시간 및 주파수 특징을 이용하는 음악 음원 분리 장치 및 방법 |
| WO2013015661A2 (fr) * | 2011-07-28 | 2013-01-31 | Ildong Pharm Co.,Ltd. | Nouveaux promédicaments de 5-(2,4-dihydroxy-5-isopropylphényl)-n-éthyl-4-(5-méthyl1-1,2,4-oxadiazol-3-yl)isoxazole-3-carboxamide |
| FR3039401B1 (fr) * | 2015-07-31 | 2018-07-13 | Les Laboratoires Servier | Nouvelle association entre le 3-[(3-{[4-(4-morpholinylmethyl)-1h-pyrrol-2-yl]methylene}-2-oxo-2,3-dihydro-1h-indol-5-yl)methyl]-1,3-thiazolidine-2,4-dione et un inhibiteur de la tyr kinase du egfr |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1611112B1 (fr) * | 2003-02-11 | 2012-08-22 | Vernalis (Cambridge) Limited | Composes d'isoxazole utiles comme inhibiteurs des proteines de choc thermique |
| US20060070405A1 (en) | 2004-10-06 | 2006-04-06 | Anheuser-Busch, Inc. | Method for the production of amber glass with reduced sulfur-containing emissions |
| EP2120900A2 (fr) | 2007-02-15 | 2009-11-25 | Novartis AG | Combinaisons d'agents thérapeutiques pour le traitement du cancer |
| WO2010069458A1 (fr) | 2008-12-17 | 2010-06-24 | Merck Patent Gmbh | Complexes d'hexahalochromate (iii) |
-
2008
- 2008-02-28 MX MX2009009233A patent/MX2009009233A/es active IP Right Grant
- 2008-02-28 EA EA200901141A patent/EA017075B1/ru not_active IP Right Cessation
- 2008-02-28 EP EP08717228A patent/EP2131845B1/fr active Active
- 2008-02-28 RS RS20120263A patent/RS52351B/sr unknown
- 2008-02-28 EP EP11192158.1A patent/EP2545921A3/fr not_active Withdrawn
- 2008-02-28 AR ARP080100831A patent/AR065519A1/es not_active Application Discontinuation
- 2008-02-28 PL PL08717228T patent/PL2131845T3/pl unknown
- 2008-02-28 BR BRPI0807992-7A2A patent/BRPI0807992A2/pt not_active IP Right Cessation
- 2008-02-28 AU AU2008220800A patent/AU2008220800B2/en not_active Ceased
- 2008-02-28 WO PCT/EP2008/052443 patent/WO2008104595A1/fr not_active Ceased
- 2008-02-28 GE GEAP200811444A patent/GEP20115309B/en unknown
- 2008-02-28 CN CN200880005490.7A patent/CN101636162A/zh active Pending
- 2008-02-28 ES ES08717228T patent/ES2384906T3/es active Active
- 2008-02-28 SI SI200830688T patent/SI2131845T1/sl unknown
- 2008-02-28 CN CN201110226727.8A patent/CN102302500A/zh active Pending
- 2008-02-28 PT PT08717228T patent/PT2131845E/pt unknown
- 2008-02-28 NZ NZ578854A patent/NZ578854A/en not_active IP Right Cessation
- 2008-02-28 CA CA002678043A patent/CA2678043A1/fr not_active Abandoned
- 2008-02-28 KR KR1020097018126A patent/KR20090122218A/ko not_active Ceased
- 2008-02-28 AT AT08717228T patent/ATE552836T1/de active
- 2008-02-28 UA UAA200908592A patent/UA101950C2/ru unknown
- 2008-02-28 HR HRP20120535AT patent/HRP20120535T1/hr unknown
- 2008-02-28 JP JP2009551218A patent/JP2010520176A/ja active Pending
- 2008-02-28 UY UY30943A patent/UY30943A1/es not_active Application Discontinuation
- 2008-02-28 US US12/529,090 patent/US8163747B2/en active Active
- 2008-02-28 DK DK08717228.4T patent/DK2131845T3/da active
- 2008-02-29 CL CL200800618A patent/CL2008000618A1/es unknown
- 2008-02-29 PA PA20088771101A patent/PA8771101A1/es unknown
- 2008-02-29 PE PE2008000418A patent/PE20090166A1/es not_active Application Discontinuation
- 2008-02-29 TW TW097107239A patent/TW200844102A/zh unknown
-
2009
- 2009-08-03 ZA ZA200905417A patent/ZA200905417B/xx unknown
- 2009-08-13 IL IL200401A patent/IL200401A0/en unknown
- 2009-08-21 CR CR10989A patent/CR10989A/es not_active Application Discontinuation
- 2009-08-28 NI NI200900161A patent/NI200900161A/es unknown
- 2009-08-28 EC EC2009009602A patent/ECSP099602A/es unknown
- 2009-08-28 TN TNP2009000357A patent/TN2009000357A1/fr unknown
- 2009-08-31 DO DO2009000209A patent/DOP2009000209A/es unknown
- 2009-08-31 GT GT200900236A patent/GT200900236A/es unknown
- 2009-08-31 MA MA32191A patent/MA31204B1/fr unknown
- 2009-09-01 CO CO09092694A patent/CO6210828A2/es not_active Application Discontinuation
- 2009-09-30 SM SM200900080T patent/SMAP200900080A/it unknown
-
2012
- 2012-03-08 US US13/415,268 patent/US8487095B2/en not_active Expired - Fee Related
- 2012-07-09 CY CY20121100610T patent/CY1113805T1/el unknown
-
2013
- 2013-07-10 US US13/938,659 patent/US20130296556A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MA31204B1 (fr) | Sels d'addition acides, hydrates et polymorphes d'ethylamide d'acide 5-(2,4-dihydroxy-5-isopropyl-phenyl) -4-(4-morpholin-4-ylmethyl-phenyl)-isoxazole-3-carboxylique et preparations comprenant ces formes | |
| PH12019501707A1 (en) | N-[4-fluoro-5-[[(2s,4s)-2-methyl-4-[(5-methyl-1,2,4-oxadiazol-3-yl)methoxy]-1-piperidyl]methyl]thiazol-2-yl]acetamide as oga inhibitor | |
| MA31084B1 (fr) | Derives de piperidine agonistes de gpcr | |
| MA42410A (fr) | Oxystérols et leurs méthodes d'utilisation | |
| TN2012000192A1 (fr) | N1-pyrazolospirocetones inhibitrices d'acetyl-coa-carboxylase | |
| EP3915566A4 (fr) | Composition pour prévenir ou traiter une maladie intestinale inflammatoire, contenant, en tant que principe actif, de l'acide taurodésoxycholique ou un sel pharmaceutiquement acceptable de ce dernier | |
| BRPI0612072A2 (pt) | inibidores da aspartil protease | |
| MA45598B1 (fr) | Stéroles 24-hydroxylés substitués en position 11 pour le traitement des maladies liées au récepteur nmda | |
| EA202092168A1 (ru) | Применение фавипиравира в лечении коронавирусной инфекции | |
| MA51204B1 (fr) | Formes pharmaceutiques comprenant un inhibiteur de la kallicréine plasmatique | |
| MA32563B1 (fr) | Dabigatran pour cathétérisme cardiaque de chirurgie percutanée | |
| NO20071314L (no) | Peptidiske vasopressinreseptoragonister | |
| EA200870577A1 (ru) | Конденсированные трициклические сульфонамидные ингибиторы гамма-секретазы | |
| MA31373B1 (fr) | Composes amino-heterocycliques | |
| MA30766B1 (fr) | Formes de dosage pharmaceutiques orales anti-manipulation contenant un analgesique opioide | |
| EA200900152A1 (ru) | Ингибиторы пирролотриазинкиназы | |
| DE602004007808D1 (de) | Neue gamma secretase inhibitoren | |
| MA31684B1 (fr) | Composition pharmaceutique contenant un antagoniste des canaux calciques de type dihydropyridine et son procédé de préparation | |
| MA30576B1 (fr) | Formes cristallines de la 4-[2-(4-methylphenylsulfanyl)-phenyl] piperidine avec inhibition de la reabsorption de la serotonine et de la norepinephrine en combinaison pour le traitement de la douleur neuropathique | |
| EA201891267A1 (ru) | Фармацевтическая композиция, содержащая действенный ингибитор urat1 | |
| NZ710574A (en) | Substituted bisphenyl butanoic phosphonic acid derivatives as nep (neutral endopeptidase) inhibitors | |
| EA200870302A1 (ru) | 1,3-диоксанкарбоновые кислоты | |
| MA41633B1 (fr) | Composés amide en tant qu'agonistes du récepteur 5-ht4 | |
| BR112018069712A2 (pt) | composto ou um sal farmacologicamente aceitável do mesmo, composição farmacêutica, método para administração de uma quantidade eficaz de uma composição farmacêutica, e, inibidor de tnf-a. | |
| MX2012001160A (es) | Agonistas del receptor de esfingosina-1-fosfato. |